Preventive effect of hot compress on phlebitis during cisplatin and Vinorelbine treatment for non-small cell lung cancer
Supportive Care in Cancer · 2026
DOI: 10.1007/s00520-026-10334-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Supportive Care in Cancer, 2026. Verfasst von Osamu Taniguchi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Hokkaido University Hospital, Kita 14-Jo, Nishi 5-Chome, Kita-Ku, Sapporo, 060-8648, Japan. Hauptthemen laut MEDLINE: Phlebitis, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Vinorelbine (VNR) is a key chemotherapeutic agent for treating non-small cell lung cancer (NSCLC). However, peripheral venous administration frequently induces phlebitis in 20-50% of patients. A previous study showed that applying a hot compress during VNR was effective in patients who had already developed symptoms. Therefore, this method was applied to all patients receiving VNR via peripheral venous administration at Hokkaido University Hospital. Herein, we aimed to evaluate the prophylactic efficacy of hot compresses for VNR-induced phlebitis in real-world settings. METHODS: Patients with NSCLC who received cisplatin (CDDP) + VNR (n = 92) were retrospectively evaluated. Patients were divided into a hot compress group, which included patients who received hot compresses during VNR administration, and a control group that did not receive hot compresses. The primary endpoint was the frequency of phlebitis during the first cycle between the groups. RESULTS: Hot compress significantly reduced the frequency of phlebitis during the first cycle (47.3% and 18.9% in the control and hot compress groups, respectively; P = 0.008) and on day 8 of the first cycle (38.2% and 10.8%; P = 0.004), with primary endpoint accomplishment. Furthermore, symptom reduction using hot compresses was confirmed among patients who received VNR on day 8 via a different arm from that administered on day 1 (31.6% vs. 3.0%, P = 0.002). Additionally, the onset of the first occurrence of VNR-induced phlebitis was significantly delayed (P = 0.008). CONCLUSION: Hot compresses significantly reduced the frequency of VNR-induced phlebitis in patients with NSCLC receiving CDDP + VNR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Hokkaido University Hospital, Kita 14-Jo, Nishi 5-Chome, Kita-Ku, Sapporo, 060-8648, Japan.
- Department of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 4-1, Maeda 7-Jo 15-Chome, Teine-Ku, Sapporo, 006-8585, Japan.
- Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Kita 15-jo, Nishi 7-Chome, Kita-ku, Sapporo, 060-8638, Japan.
- Department of Pharmacy, Hokkaido University Hospital, Kita 14-Jo, Nishi 5-Chome, Kita-Ku, Sapporo, 060-8648, Japan. msuga@pharm.hokudai.ac.jp.
- Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12-Jo, Nishi 6-Chome, Kita-Ku, Sapporo, 060-0812, Japan. msuga@pharm.hokudai.ac.jp.
Zitieren
APA
Taniguchi, O., Saito, Y., Sakamoto, T., Sakakibara-Konishi, J., Takekuma, Y., & Sugawara, M. (2026). Preventive effect of hot compress on phlebitis during cisplatin and Vinorelbine treatment for non-small cell lung cancer. Supportive Care in Cancer. https://doi.org/10.1007/s00520-026-10334-5
Vancouver
Taniguchi O, Saito Y, Sakamoto T, Sakakibara-Konishi J, Takekuma Y, Sugawara M. Preventive effect of hot compress on phlebitis during cisplatin and Vinorelbine treatment for non-small cell lung cancer. Supportive Care in Cancer. 2026. doi:10.1007/s00520-026-10334-5
BibTeX
@article{Taniguchi2026,
author = {Taniguchi, Osamu and Saito, Yoshitaka and Sakamoto, Tatsuhiko and Sakakibara-Konishi, Jun and Takekuma, Yoh and Sugawara, Mitsuru},
title = {Preventive effect of hot compress on phlebitis during cisplatin and Vinorelbine treatment for non-small cell lung cancer},
journal = {Supportive Care in Cancer},
year = {2026},
doi = {10.1007/s00520-026-10334-5}
}
EUVIMED